Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.

Love D, Stratton E, Stocum M.

N Biotechnol. 2012 Sep 15;29(6):689-94. doi: 10.1016/j.nbt.2012.06.005. Epub 2012 Jun 25. Review.

PMID:
22743138
2.

Do companion diagnostics make economic sense for drug developers?

Agarwal A.

N Biotechnol. 2012 Sep 15;29(6):695-708. doi: 10.1016/j.nbt.2012.04.004. Epub 2012 May 1. Review.

PMID:
22575210
3.

The biomarker is not the end.

Nohaile M.

Drug Discov Today. 2011 Oct;16(19-20):878-83. doi: 10.1016/j.drudis.2011.08.011. Epub 2011 Aug 24. Review.

PMID:
21888986
4.

Predictive markers in early research and companion diagnostic developments in oncology.

Pickl M, Ruge E, Venturi M.

N Biotechnol. 2012 Sep 15;29(6):651-5. doi: 10.1016/j.nbt.2012.03.008. Epub 2012 Mar 30. Review.

PMID:
22484859
5.

Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.

Roscoe DM, Hu YF, Philip R.

Expert Rev Mol Diagn. 2015;15(7):869-80. doi: 10.1586/14737159.2015.1045490. Review.

PMID:
26109316
6.

[Diagnostic kits in parasitology: which controls?].

Rossi P.

Parassitologia. 2004 Jun;46(1-2):145-9. Review. Italian.

PMID:
15305705
7.

Molecular tools for companion diagnostics.

Zieba A, Grannas K, Söderberg O, Gullberg M, Nilsson M, Landegren U.

N Biotechnol. 2012 Sep 15;29(6):634-40. doi: 10.1016/j.nbt.2012.05.004. Epub 2012 May 24. Review.

PMID:
22634023
8.

Evaluating the value of genomic diagnostics: implications for clinical practice and public policy.

Issa AM.

Adv Health Econ Health Serv Res. 2008;19:191-206. Review.

PMID:
19548519
9.

The current and future state of companion diagnostics.

Agarwal A, Ressler D, Snyder G.

Pharmgenomics Pers Med. 2015 Mar 31;8:99-110. doi: 10.2147/PGPM.S49493. eCollection 2015. Review.

10.

Point-of-care diagnostics: will the hurdles be overcome this time?

Huckle D.

Expert Rev Med Devices. 2006 Jul;3(4):421-6. Review.

PMID:
16866639
11.

New ways of insulin delivery.

Heinemann L.

Int J Clin Pract Suppl. 2011 Feb;(170):31-46. doi: 10.1111/j.1742-1241.2010.02577.x. Review.

PMID:
21323811
12.

Market power in the United States red meatpacking industry.

Koontz SR.

Vet Clin North Am Food Anim Pract. 2003 Jul;19(2):519-44. Review.

PMID:
12951745
13.

The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics.

Trusheim MR, Berndt ER.

Drug Discov Today. 2015 Dec;20(12):1439-50. doi: 10.1016/j.drudis.2015.10.017. Epub 2015 Nov 3. Review.

PMID:
26542060
14.

[Biomarkers: "Found in translation"].

Lockhart BP, Walther B.

Med Sci (Paris). 2009 Apr;25(4):423-30. doi: 10.1051/medsci/2009254423. Review. French.

15.

Drug-diagnostic co-development: challenges and issues.

Shimazawa R, Ikeda M.

Expert Rev Mol Diagn. 2016;16(2):187-204. doi: 10.1586/14737159.2016.1132163. Epub 2016 Jan 13. Review.

PMID:
26651878
16.

[Competition and prices in the Mexican pharmaceutical market].

Molina-Salazar RE, González-Marín E, Carbajal-de Nova C.

Salud Publica Mex. 2008;50 Suppl 4:S496-503. Review. Spanish.

17.

Developing precision medicine in a global world.

Rubin EH, Allen JD, Nowak JA, Bates SE.

Clin Cancer Res. 2014 Mar 15;20(6):1419-27. doi: 10.1158/1078-0432.CCR-14-0091. Review.

18.

Practical guidance for implementing predictive biomarkers into early phase clinical studies.

Marton MJ, Weiner R.

Biomed Res Int. 2013;2013:891391. doi: 10.1155/2013/891391. Epub 2013 Oct 22. Review.

19.

[International comparison and regulatory issues of the molecular targeted therapy development].

Iwasaku M, Kawakami K.

Nihon Rinsho. 2015 Aug;73(8):1403-8. Review. Japanese.

PMID:
26281697
20.

Supplemental Content

Support Center